Paris (France), 11 May 2009 - Jean-Christophe Tellier has joined the Ipsen Group (Euronext: FR0010259150; IPN) as President and General manager of Ipsen’s North American operations, effective 1st May 2009. He will report to Christophe Jean, Executive Vice-President, Chief Operating Officer. J-C. Tellier will be based in Brisbane, CA.

<br><A href="http://ad.doubleclick.net/jump/PharmaLive/main;sz=300x250;abr=!ie4;abr=!ie5;ord=1242079735907?"> <IMG src="http://ad.doubleclick.net/ad/PharmaLive/main;sz=300x250;abr=!ie4;abr=!ie5;ord=1242079735907?" width="300" height="250" border=0 ALT=""></A>

Jean-Christophe Tellier’s mission will be to strengthen Ipsen’s franchises in North America, with four drugs available: • in endocrinology, Somatuline® Depot is indicated for the long-term treatment of acromegaly (in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option) and Increlex® for the long-term treatment of growth failure (in children and adolescents with severe primary insulin-like growth factor 1 deficiency, primary IGFD), • in neurology, Apokyn® is indicated for the treatment of “off” episodes in moderate to severe Parkinson’s Disease, and Dysport™ recently received the approval by the Food and Drug Administration.

Jean-Christophe Tellier started his career in 1988 in the marketing department of Synthélabo and joined Ciba France as Group Marketing Manager and Head of the Hospital Business in 1990. In 1997, following the merger of Ciba and Sandoz to form Novartis, Dr. Tellier was appointed Head of the Mass Market Business unit in France until the end of 2002 where he became Chief Operating Officer of Novartis France. From 2003 to mid-2006, Dr. Tellier was CEO of Novartis Pharma Belgium and became the first non Belgian elected to head the Belgian Pharma Industry Association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, Dr. Tellier was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Maryland-based biotechnology company, as Executive Vice President and Chief Commercial Officer.

Jean-Christophe Tellier (49 years old) is a physician specialized in rheumatology (University of Paris V, France). He holds a diploma from the European Marketing Programme at Insead (Fontainebleau, France) and has attended several management courses at IMD (Lausanne, Switzerland) and Harvard Business School (Boston, MA, USA).

About Ipsen Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the “Service de Règlement Différé” (“SRD”) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.Ipsen.com.

For further information: Ipsen Media Didier Véron Director, Public Affairs and Corporate Communications Tel.: +33 (0)1 58 33 51 16 Fax: +33 (0)1 58 33 50 58 E-mail: didier.veron@ipsen.com Financial Community David Schilansky Pierre Kemula Investor Relations Officer Tel.: +33 (0)1 58 33 51 30 Fax: +33 (0)1 58 33 50 63 E-mail: david.schilansky@ipsen.com Investor Relations Manager Tel.: +33 (0)1 58 33 60 08 Fax: +33 (0)1 58 33 50 63 E-mail: pierre.kemula@ipsen.com